The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Open accessAbstract
BACKGROUND: For patients with smoldering multiple myeloma, the standard of care is observation until symptoms develop. However, this approach does not identify high-risk patients who may benefit from early intervention. METHODS: In this randomized, open-label, phase 3 trial, we randomly assigned 119 patients with high-risk smoldering myeloma to treatment or observation. Patients in the treatment group received an induction regimen (lenalidomide at a dose of 25 mg per day on days 1 to 21, plus dexamethasone at a dose of 20 mg per day on days 1 to 4 and days 12 to 15, at 4-week intervals for nine cycles), followed by a maintenance regimen (lenalidomide at a dose of 10 mg per day on days 1 to 21 of each 28-day cycle for 2 years). The primary end point was time to progression to symptomatic disease. Secondary end points were response rate, overall survival, and safety. RESULTS: After a median follow-up of 40 months, the median time to progression was significantly longer in the treatment group than in the observation group (median not reached vs. 21 months; hazard ratio for progression, 0.18; 95% confidence interval [CI], 0.09 to 0.32; P<0.001). The 3-year survival rate was also higher in the treatment group (94% vs. 80%; hazard ratio for death, 0.31; 95% CI, 0.10 to 0.91; P=0.03). A partial response or better was achieved in 79% of patients in the treatment group after the induction phase and in 90% during the maintenance phase. Toxic effects were mainly grade 2 or lower. CONCLUSIONS: Early treatment for patients with high-risk smoldering myeloma delays progression to active disease and increases overall survival. (Funded by Celgene; ClinicalTrials.gov number, NCT00480363.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Early therapy with lenalidomide and dexamethasone or single-agent lenalidomide is beneficial in patients with high risk smoldering multiple myeloma, and is discussed separately.104,105”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [104]
The cited source says what the claim attributes to it.
In the citing paper
“A randomized trial conducted in Spain found that patients with high risk SMM had significant prolongation of PFS and OS with Rd compared with observation.104,197”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [104]
The cited source says what the claim attributes to it.
In the citing paper
“Several trials have reported the advantages and risks of early intervention in high risk SMM.105-112”
From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [106]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,367
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Rajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citationRajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933
Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921
Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
Palumbo, A. P., Hájek, R., Delforge, M., Kropff, M. H., Petrucci, M. T., Catalano, J. V., Gisslinger, H., Wiktor-Jędrzejczak, W., Zodelava, M., Weisel, K. C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112704 · Cited by 748
Self-citationPérez-Persona, E., Vidriales, M.-B., Mateo, G., García-Sanz, R., Mateos, M.-V., de Coca, A. G., Galende, J., Martín-Nuñez, G., Alonso, J. M., de las Heras, N., et al. (2007) · Blood · doi:10.1182/blood-2007-05-088443 · Cited by 579
Self-citationThalidomide Alone or With Dexamethasone for Previously Untreated Multiple Myeloma
Weber, D., Rankin, K., Gavino, M., Delasalle, K. B., & Alexanian, R. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.139 · Cited by 565
Dispenzieri, A. A., Kyle, R. A., Katzmann, J. A., Therneau, T. M., Larson, D. R., Benson, J. T., Clark, R. J., Melton, L. J., Gertz, M. A., Kumar, S. K., et al. (2007) · Blood · doi:10.1182/blood-2007-08-108357 · Cited by 432
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,000
Palma, B. D., Marchica, V., Pedrazzoni, M., Accardi, F., Notarfranchi, L., Goldoni, M., Luca, F. D., Costa, F., Storti, P., Toscani, D., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.15026 · Cited by 5
Diagnosis and Staging of Multiple Myeloma and Related Disorders
Rajkumar, S. V., Fonseca, R., & Miguel, J. F. S. (2017) · Hematologic malignancies · doi:10.1007/978-3-319-25586-6_2 · Cited by 5
[Biology of articular cartilage repair--present status and prospects].
Uchio, Y., & Ochi, M. (2004) · PubMed · Cited by 5
Manasanch, E. E., Kunacheewa, C., Claussen, C. M., Lee, H. C., Thomas, S. K., Gunther, J. R., Pinnix, C. C., Dabaja, B. S., Amini, B., Alexanian, R., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00419-1 · Cited by 5
Kitson, A. L., Taylor, A. S., Giacherio, D. A., & Keren, D. F. (2021) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqab108 · Cited by 5
Bhargav, H., Huilgol, V., Metri, K., Sundell, I. B., Tripathi, S., Ramagouda, N., Jadhav, M., Nagarathna, R., Ramarao, N. H., & Koka, P. S. (2012) · PubMed · Cited by 5
Nagy, Z. (2013) · PubMed · Cited by 5
Song, Z., Ma, L., Bao, L., Ma, Y., Yang, P., Jiang, D. L., Liu, A., Zhang, L., Li, Y., Cheng, Y., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.931495 · Cited by 6
Ishida, Y. (2008) · PubMed · Cited by 5
Rafique, M. (2003) · PubMed · Cited by 5
Munshi, N. C., & Jagannath, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00086-x · Cited by 5
Similar neurocognitive patterns in patients treated with lenalidomide: chemobrain effect?
Calvi, E., Marchetti, M., Santagata, F., Luppi, C., Coppo, E., Massaia, M., & Isaia, G. C. (2019) · Neurocase · doi:10.1080/13554794.2019.1666876 · Cited by 5
“and, in recent years, non-Hodgkin mantle cells lymphoma (Arora & Portell, 2018; Mateos et al., 2013; Rao, 2007).”
Background[Endocrine therapy for prostate cancer.]
Nagaya, N., & Horie, S. (2018) · PubMed · Cited by 5
[Pharmacological treatment for pregnancy and lactation associated osteoporosis.]
Kitajima, M., & Chaki, O. (2019) · PubMed · Cited by 5
[Mechanism of vascular calcification].
Shioi, A. (2002) · PubMed · Cited by 5
Nawaz, H., Khan, S., Ahmed, S., Khan, M., Pervaiz, A., & Khan, S.-U.-D. (2003) · PubMed · Cited by 5
Smoldering multiple myeloma: to treat or not to treat
Gentile, M., Offidani, M., Vigna, E., Corvatta, L., Recchia, A. G., Morabito, L., Martino, M. V., Morabito, F., & Gentili, S. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1007952 · Cited by 5
“Although for the first time in the history of SMM, a therapy demonstrated a significant delay in TTP improving OS, other studies did not find similar results and more data from randomized, multicenter trials are needed before identifying this approach as a standard of care [17].”
BackgroundResultFrederico Adolfo Simões Barbosa ( 1916 †2004)
(2004) · Revista da Sociedade Brasileira de Medicina Tropical · doi:10.1590/s0037-86822004000500015 · Cited by 5
Molecular and immunological determinants of long-term survival in multiple myeloma
Kasomva, K., Yadav, K., Janz, S., Dhakal, B., & Rao, S. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016829 · Cited by 4
Multi-omics profiling and AI-driven clinically deployable risk models in MGUS and smoldering myeloma
Wu, Y., Zhang, D., Jiang, J., Zheng, L., Zhou, Z., Zhang, Z., & Nouri, S. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01987-3 · Cited by 5
Immune biomarkers of increased infection risk in multiple myeloma
Zabaleta, A., Tamariz‐Amador, L., Kostopoulos, I. V., Sklavenitis‐Pistofidis, R., Smits, F., Rodríguez‐Otero, P., Roncal, C., Aranha, M. P., Žihala, D., Machu, M., et al. (2026) · Blood · doi:10.1182/blood.2025031744 · Cited by 5
Self-citationMittelman, M., Israel, A., Oster, H. S., Leshchinsky, M., Ben‐Shlomo, Y., Kepten, E., Dolberg, O. J., Balicer, R. D., & Shaham, G. (2025) · British Journal of Haematology · doi:10.1111/bjh.20136 · Cited by 4
Miyaki, S. (2018) · PubMed · Cited by 4
Choi, S., Kim, E., Jung, J., Park, S., Min, C., & Han, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-52720-1 · Cited by 4
“Nonetheless, as noted above, several studies have reported that early intervention with a combination of lenalidomide and dexamethasone provided benefits with respect to progression-free and overall survival in non-symptomatic MM patients at high risk of developing MM 34 .”
Advances in the management of asymptomatic myeloma
Mateos, M. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000121 · Cited by 4
Self-citationHigh-risk smoldering myeloma: Perspective on watchful monitoring
Leng, S., & Lentzsch, S. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.11.001 · Cited by 4
Monoklonale Gammopathie unklarer Signifikanz und multiples Myelom
Schmalzing, M., Tony, H., & Knop, S. T. (2017) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-017-0335-z · Cited by 4
“IneineraktuellenStudiebeiPatientenmit „smoldering myeloma“ mit hohem Progressionsrisiko konnte aber für die Therapie mit Lenalidomid/Dexamethason im Vergleich zu „watch and wait“ nicht nur ein Vorteil für das progressionsfreie Überleben, sondern sogar ein Gesamtüberlebensvorteil nachgewiesen werden [3].”
Coexistence of primary colorectal follicular lymphoma and multiple myeloma: a case report
Saito, M., Miyashita, K., Miura, Y., Ogasawara, R., Kanaya, M., Izumiyama, K., Mori, A., Kondo, T., Tanaka, M., Morioka, M., et al. (2018) · International Journal of General Medicine · doi:10.2147/ijgm.s171387 · Cited by 4
“16 The simultaneous occurrence of lymphoma and MM within the same patient is rare.”
(2018) · PubMed · Cited by 4
Shimizu, H., Hironori Nakagami, A., & Morishita, R. (2014) · PubMed · Cited by 4
Free and total prostate specific antigen in benign prostate hyperplasia and prostate cancer.
Naz, S., Ahmad, S., Ghafoor, F., Butt, N. S., & Akhtar, M. W. (2004) · PubMed · Cited by 4
Progress in the Management of Smoldering Multiple Myeloma
Schmidt, T. M., & Callander, N. S. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00623-7 · Cited by 6
Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings?
Lionetti, M., Vià, M. D., Albano, F., Neri, A., Bolli, N., & Musto, P. (2021) · Cancers · doi:10.3390/cancers13133319 · Cited by 4
“As well as the first results [51], also the long follow-up analysis [52] highlighted an improvement in the time to progression in patients who underwent treatment.”
ResultChoi, T., Ahn, W., Shin, D. W., Han, K., Kim, D., & Chun, S. (2021) · Cancer Research and Treatment · doi:10.4143/crt.2021.951 · Cited by 4
“Need for SMM treatment has been the topic of hot debates in the myeloma field, and more evidence is amassing for treating SMM [29-32].”
Hussain, M., Baig, F. A., & Hussain, S. (2007) · PubMed · Cited by 4
Miyakoshi, N. (2008) · PubMed · Cited by 4
Eliyahu, L., Zohar Yosibash, A., Avivi, I. M., Cohen, Y. C., Ariel, G., Sadovnic, O., & Sternheim, A. (2023) · Clinical Biomechanics · doi:10.1016/j.clinbiomech.2023.105889 · Cited by 4
Diagnostic and Prognostic Value of PACAP in Multiple Myeloma
Tóth, T., Alizadeh, H., Polgár, B., Csalódi, R., Reglődi, D., & Tamás, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310801 · Cited by 5
“The latter modification was necessary because a randomized trial showed that the treatment of patients with high-risk SMM could improve their survival [37].”
BackgroundEarly Detection of Precursor Diseases of Multiple Myeloma
O’Donnell, E., Borden, B. A., & Ghobrial, I. M. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.03.003 · Cited by 4
[Body weight and bone/calcium metabolism. Muscle, myokines and bone/calcium metabolism.]
Kaji, H. (2018) · PubMed · Cited by 4
[Rickets/Osteomalacia. Consensus on Vitamin D Deficiency and Insufficiency in Children.]
Michigami, T. (2018) · PubMed · Cited by 4
Nishimura, R. (2011) · PubMed · Cited by 4
Ogawa, H., & Akiyama, H. (2018) · PubMed · Cited by 4
Iwamoto, J. (2017) · PubMed · Cited by 4
Secondary Infertility due to Retained Fetal Bones Diagnosed via Saline Sonography.
Izhar, R., Husain, S., Tahir, S., & Husain, S. (2016) · PubMed · Cited by 4
Zhen, Y., Shang, B.-Y., Liu, X., Lin, Y., & Zhen, Y. (2016) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.146093 · Cited by 4
Recent Advances in Biology and Treatment of Multiple Myeloma
Abe, M. (2015) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.104.305 · Cited by 4
Mochizuki, S.-I., Kiyokawa, A., & Nagayama, Y. (2005) · PubMed · Cited by 4
Oncologist perspective: role of imaging in myeloma
Shapiro, Y. N., & O’Donnell, E. (2021) · Skeletal Radiology · doi:10.1007/s00256-021-03856-y · Cited by 4
[Treatment of malignancy associated hypercalcemia].
Endo, I., & Inoue, D. (2006) · PubMed · Cited by 4
Acute hemorrhagic edema of infancy
Javidi, Z., Maleki, M., Mashayekhi, V., Tayebi-Maybodi, N., & Nahidi, Y. (2004) · Springer eBooks · doi:10.1007/3-540-29668-9_104 · Cited by 4
Manasanch, E. E., Korde, N., Mailankody, S., Tageja, N., Bhutani, M., Roschewski, M. J., & Landgren, O. (2014) · Haematologica · doi:10.3324/haematol.2014.107516 · Cited by 4
“A recent trial has shown that early intervention delays end-organ damage and can alter the course of the disease.(6) As extrapolated from other medical conditions, including other solid and hematologic malignancies, one may conjecture that early intervention has the potential to provide a path to a cure in myeloma.”
BackgroundNeonatal complications in infants born to diabetic mothers.
Akhtar, J., Ahmed, S., Soomro, M. A., Zamir, N., & Sharif, A. (2006) · PubMed · Cited by 4
Should high risk smoldering myeloma be treated outside a clinical trial: NO
Gertz, M. A., & Vaxman, I. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1951723 · Cited by 4
“Only a single clinical trial has reported survival benefit in treating high-risk smoldering multiple myeloma [4].”
BackgroundShah, S. A., Altaf, A., Khanani, R., & Vermund, S. H. (2005) · PubMed · Cited by 4
Tratamiento del mieloma múltiple asintomático: recomendaciones del Grupo Español de Mieloma
Mateos, M., Bladé, J., Lahuerta, J. J., & Miguel, J. F. S. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.02.012 · Cited by 3
Self-citationMiyakoshi, N. (2014) · PubMed · Cited by 3
Agarwal, G., Nador, G., Varghese, S., Getu, H., Palmer, C., Watson, E., Pereira, C., Sallemi, G., Partington, K. J., Patel, N., et al. (2022) · Cancers · doi:10.3390/cancers15010095 · Cited by 3
“Such markers may additionally capture a subset of smouldering MM (SMM) patients that may benefit from earlier treatment [3,4] and refine monitoring frequency in monoclonal gammopathy of undetermined significance (MGUS) [5].”
BackgroundSolitary bone plasmacytoma: Long-term clinical outcomes in a single center
Gao, S., Wang, Y.-T., Ma, G., Lu, M., Chu, B., Shi, L., Fang, L., Xiang, Q., Ding, Y.-H., & Bao, L. (2024) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2024.101095 · Cited by 3
Slovenske smernice za obravnavo diseminiranega plazmocitoma 2015
Zver, S., & Mlakar, U. (2015) · Slovenian Medical Journal · doi:10.6016/zdravvestn.1343 · Cited by 3
How long can we let the myeloma smolder?
Usmani, S. Z. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.874944 · Cited by 3
“[6] have recently reported a small Phase III trial in AMM showing improvement in survival outcomes.”
BackgroundDevelopments in the Field of Myeloma in the Last Decade
Saikia, T. K. (2017) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-017-0777-0 · Cited by 3
[Aging-related frailty and sarcopenia. Frailty/sarcopenia and insulin/IGF-1 signaling.]
Sasako, T., & Ueki, K. (2018) · PubMed · Cited by 3
[Bone fragility in type 1 diabetes and type 2 diabetes.]
Fukui, T., & Takahashi, Y. (2019) · PubMed · Cited by 3
Recent Advances in the Management of Smoldering Multiple Myeloma
Madhira, B. R., Konala, V. M., Adapa, S., Naramala, S., Ravella, P. M., Parikh, K., & Gentile, T. (2020) · World Journal of Oncology · doi:10.14740/wjon1245 · Cited by 3
“Mateos et al (2013) [39] RCT Lenalidomide and dexamethasone versus observation Treatment: TTP NR; observation: TTP 21 months 5-year OS; treatment: 94 months, observation: 78 months”
BackgroundMethodResultInfluential[Primary fracture prevention through the Osteoporosis Liaison Service.]
Nakatoh, S. (2017) · PubMed · Cited by 3
Son, A. Y., & Chung, H. W. (2022) · Journal of the Korean Society of Radiology · doi:10.3348/jksr.2021.0179 · Cited by 3
“하지만 다발성 골수종에 대한 치료법이 발전하게 되었고 증상이 없는 고위험군 환자에게 조기 치료를 하 였을 때 환자의 생존율이 올라간다는 데이터들이 축적되면서, 조기 진단과 치료를 가능하게 하는 명 확한 진단기준의 필요성이 대두되었다(8, 9).”
Hasan, N., & Razzaq, A. (2004) · PubMed · Cited by 3
Daratumumab, Lenalidomide, and Dexamethasone for High-Risk Smoldering Multiple Myeloma
Tan, C. R. C., & Usmani, S. Z. (2023) · The Hematologist · doi:10.1182/hem.v20.2.202329 · Cited by 3
Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma
Grosicki, S., & Barchnicka, A. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1199947 · Cited by 3
“with len/dex regimen is beneficial [47].”
[Aging and homeostasis. Aging of articular cartilage and chondrocytes.]
Matsushita, T., & Tanaka, T. (2017) · PubMed · Cited by 3
Murakami, K., & Mimori, T. (2018) · PubMed · Cited by 3
[Oral healthcare for the persons with special needs.]
Morisaki, I. (2017) · PubMed · Cited by 3
[Taste receptors in multiple organs.]
Iwatsuki, K., & Nakajima, C. (2018) · PubMed · Cited by 3
Yakabe, M. (2018) · PubMed · Cited by 3
[Pathophysiology of bone and calcium metabolism in young women.]
白土, な. (2019) · PubMed · Cited by 3
How We Manage Smoldering Multiple Myeloma
Romano, A., Cerchione, C., Conticello, C., Martinelli, G., & Raimondo, F. D. (2020) · Hematology Reports · doi:10.4081/hr.2020.8951 · Cited by 4
Therapie des multiplen Myeloms
Peest, D., Ganser, A., & Einsele, H. (2013) · Der Internist · doi:10.1007/s00108-013-3323-7 · Cited by 3
Fouquet, G., Guidez, S., Herbaux, C., Demarquette, H., & Leleu, X. P. (2013) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2013.08.004 · Cited by 3
Treatment of Smoldering Myeloma: Early or Delayed?
Fermand, J. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.12.008 · Cited by 3
Smith, M. R. (1939) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.26523 · Cited by 3
Treatment of high-risk smoldering myeloma
Korde, N. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.11.005 · Cited by 3
Two related cases of primary complement deficiencies.
Farhoudi, A., Bazargan, N., Pourpak, Z., & Mahmoudi, M. (2003) · PubMed · Cited by 3
Khalid, L., Ali, I., Wahid, K., Khan, A. U., & Fawad, S. (2016) · PubMed · Cited by 3
Inoue, A., & Harada, K. (2017) · PubMed · Cited by 3
[Thermoregulatory behavior and its central circuit mechanism-What thermosensory pathway drives it?]
Nakamura, K. (2018) · PubMed · Cited by 3
[Aging and homeostasis. Chronic inflammation and aging.]
Akazawa, H. (2017) · PubMed · Cited by 3
Kato, S., Nishimura, K., & Mori, J. (2017) · PubMed · Cited by 3
Kameda, H. (2018) · PubMed · Cited by 3
[Growth spurts of the bone from infancy to puberty.]
Ohta, H. (2019) · PubMed · Cited by 3
[Olfactory receptors expressed in various non-olfactory tissues.]
Ihara, S., & Touhara, K. (2018) · PubMed · Cited by 3
[Implementation of Fracture Liaison Service for a secondary prevention of fragility fracture.]
Yamamoto, N. (2017) · PubMed · Cited by 3
Okazaki, R. (2011) · PubMed · Cited by 3
Mitsui, H. (2008) · PubMed · Cited by 3
[The role of SASP in tumor microenvironment.]
Ohtani, N. (2017) · PubMed · Cited by 3
[Aging-related frailty and sarcopenia. Frailty - Sarcopenia and biomarker.]
Inoue, A., Kuzuya, M., & Xianwu, C. (2018) · PubMed · Cited by 3
Martínez‐Cordero, H., Martínez, L. M., Idárraga, J. A. O., Argüelles, G. R., Polo, V. A., Ojeda, C. P., Roa, M., de Larrea, C. F., Jiménez, R. O. R., Fantl, D. B. E., et al. (2020) · Revista Colombiana de Cancerología · doi:10.35509/01239015.656 · Cited by 4
COOPER, D. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.7712 · Cited by 3
Chromosomal analysis in epilepsy.
Sultan, T., Malik, M. A., & Khan, M. M. N. (2007) · PubMed · Cited by 3
Using genomics to better define high-risk MGUS/SMM patients
Dutta, A. K., Hewett, D. R., Fink, J. L., & Zannettino, A. C. W. (2018) · Oncotarget · doi:10.18632/oncotarget.26390 · Cited by 3
Metadata
- Authors
- Mateos, M.-V., Hernández, M.-T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., Oriol, A., Prosper, F., López, J., Olavarría, E., Quintana, N., García, J.-L., Bladé, J., Lahuerta, J.-J., & San Miguel, J.-F.
- Affiliations
- Consejo Superior de Investigaciones Científicas (ES)
- Universidad de Salamanca (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-08
- Volume
- 369
- Issue
- 5
- Pages
- 438-447
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2144930991
- Semantic Scholar
- 26670ff667b1b637856dff4325d13f38e1b7d641
- Cited by
- 1,171
- References
- 29
- Citations by year
- 2026: 23 · 2025: 36 · 2024: 37 · 2023: 29 · 2022: 64 · 2021: 47 · 2020: 63 · 2019: 52 · 2018: 195 · 2017: 145 · 2016: 82 · 2015: 57 · 2014: 63 · 2013: 26
- FWCI
- 54.54
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Hispana (publishedVersion, cc-by-nc-nd)
- Gredos (University of Salamanca) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- smoldering multiple myeloma, lenalidomide, dexamethasone, early treatment, time to progression, overall survival, maintenance therapy, induction therapy, high-risk myeloma
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Myeloma, Risk, Thalidomide, Survival Rate, Disease Progression, Induction Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
